NasdaqGS:XBIT

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. More Details


Snowflake Analysis

Flawless balance sheet and fair value.

Share Price & News

How has XBiotech's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: XBIT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: XBIT's weekly volatility has decreased from 15% to 8% over the past year.


Market Performance


7 Day Return

11.4%

XBIT

1.9%

US Biotechs

2.1%

US Market


1 Year Return

68.8%

XBIT

21.2%

US Biotechs

19.8%

US Market

Return vs Industry: XBIT exceeded the US Biotechs industry which returned 21.2% over the past year.

Return vs Market: XBIT exceeded the US Market which returned 19.8% over the past year.


Shareholder returns

XBITIndustryMarket
7 Day11.4%1.9%2.1%
30 Day15.6%6.5%8.1%
90 Day3.1%7.1%6.0%
1 Year68.8%68.8%23.3%21.2%22.5%19.8%
3 Year368.4%368.4%21.7%15.4%46.5%36.8%
5 Year125.2%125.2%14.9%7.0%96.9%75.3%

Long-Term Price Volatility Vs. Market

How volatile is XBiotech's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is XBiotech undervalued compared to its fair value and its price relative to the market?

0.97x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate XBIT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate XBIT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: XBIT is good value based on its PE Ratio (1x) compared to the US Biotechs industry average (28.4x).

PE vs Market: XBIT is good value based on its PE Ratio (1x) compared to the US market (19.7x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate XBIT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: XBIT is good value based on its PB Ratio (1.6x) compared to the US Biotechs industry average (3.5x).


Next Steps

Future Growth

How is XBiotech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

20.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as XBiotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has XBiotech performed over the past 5 years?

82.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: XBIT has a high level of non-cash earnings.

Growing Profit Margin: XBIT became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: XBIT has become profitable over the past 5 years, growing earnings by 82.1% per year.

Accelerating Growth: XBIT has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: XBIT has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.8%).


Return on Equity

High ROE: XBIT's Return on Equity (195.6%) is considered outstanding.


Next Steps

Financial Health

How is XBiotech's financial position?


Financial Position Analysis

Short Term Liabilities: XBIT's short term assets ($251.7M) exceed its short term liabilities ($6.2M).

Long Term Liabilities: XBIT's short term assets ($251.7M) exceed its long term liabilities ($1.1M).


Debt to Equity History and Analysis

Debt Level: XBIT is debt free.

Reducing Debt: XBIT has not had any debt for past 5 years.

Debt Coverage: XBIT has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: XBIT has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is XBiotech current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate XBIT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate XBIT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if XBIT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if XBIT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of XBIT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

John Simard (58 yo)

15.67yrs

Tenure

US$10,810,362

Compensation

Mr. John Simard is the Founder of XBiotech, Inc. and serves as its Chairman and has been its Chief Executive Officer and President since March 2005. Mr. Simard serves as the Chairman, Chief Executive Offic...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD10.81M) is above average for companies of similar size in the US market ($USD1.79M).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
John Simard
Founder15.67yrsUS$10.81m12.72%
$ 68.6m
Queena Han
VP of Finance & Human Resources and Secretaryno dataUS$1.07m0.20%
$ 1.1m
Sushma Shivaswamy
Chief Scientific Officer3yrsUS$1.43m0%
$ 0
Lisa Simard
Director of Corporpate Strategy - XBiotech USAno datano datano data
Benjamín Guzmán
Senior Vice President of Corporate Strategy & Finance3.33yrsno datano data

3.3yrs

Average Tenure

55.5yo

Average Age

Experienced Management: XBIT's management team is considered experienced (3.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
John Simard
Founder15.67yrsUS$10.81m12.72%
$ 68.6m
W. McKenzie
Independent Director11.75yrsUS$137.00k8.89%
$ 47.9m
Donald MacAdam
Independent Director2.67yrsUS$137.00k0%
$ 0
Peter Libby
Member of Scientific Advisory Board & Independent Director1.33yrsUS$137.00k0.043%
$ 230.3k
Alice Gottlieb
Member of Scientific Advisory Board2.17yrsno datano data
Alexander Knuth
Member of Scientific Advisory Board3.58yrsno datano data
Razelle Kurzrock
Member of Scientific Advisory Board3.58yrsno datano data
Andrew Hendifar
Member of Scientific Advisory Board3.58yrsno datano data
Jan-Paul Waldin
Lead Independent Directorno dataUS$137.00k0.68%
$ 3.7m
Evangelos Giamarellos-Bourboulis
Member of Scientific Advisory Boardno datano datano data
Mark Rupp
Member of Scientific Advisory Boardno datano datano data

3.6yrs

Average Tenure

71yo

Average Age

Experienced Board: XBIT's board of directors are considered experienced (3.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: XBIT insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

XBiotech Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: XBiotech Inc.
  • Ticker: XBIT
  • Exchange: NasdaqGS
  • Founded: 2005
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$538.980m
  • Shares outstanding: 29.26m
  • Website: https://www.xbiotech.com

Number of Employees


Location

  • XBiotech Inc.
  • 5217 Winnebago Lane
  • Austin
  • Texas
  • 78744
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
XBITNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDApr 2015
4XBDB (Deutsche Boerse AG)YesCommon StockDEEURApr 2015

Biography

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of antibody ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/27 23:48
End of Day Share Price2020/11/27 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.